Sun Pharmaceutical Industries Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Price Momentum and Recent Market Performance

On 18 Feb 2026, Sun Pharma closed at ₹1,718.50, up from the previous close of ₹1,699.75, marking a daily increase of 1.10%. The intraday range was relatively tight, with a low of ₹1,694.45 and a high of ₹1,719.05, indicating measured buying interest. The stock remains below its 52-week high of ₹1,850.95 but comfortably above the 52-week low of ₹1,547.25, suggesting resilience amid broader market fluctuations.

Comparatively, Sun Pharma has outperformed the Sensex over multiple time horizons. Over the past week, the stock returned 0.64% while the Sensex declined by 0.98%. Over one month, Sun Pharma gained 2.95% against a marginal Sensex loss of 0.14%. Year-to-date, the stock is nearly flat (-0.07%) compared to the Sensex’s 2.08% decline. Longer-term returns are particularly impressive, with a 3-year gain of 74.72% versus the Sensex’s 36.80%, and a 5-year return of 176.64% compared to the Sensex’s 61.40%. However, the 10-year return of 101.10% trails the Sensex’s 256.90%, reflecting sector-specific challenges over the last decade.

Technical Indicators: A Mixed Picture

The technical landscape for Sun Pharma is characterised by a blend of bullish and bearish signals across different timeframes and indicators. The daily moving averages have turned bullish, signalling short-term upward momentum. This is a positive development, as moving averages often act as dynamic support and resistance levels, and a bullish crossover can attract momentum traders.

However, the weekly and monthly MACD (Moving Average Convergence Divergence) indicators remain bearish or mildly bearish, respectively. The weekly MACD’s bearish stance suggests that momentum on a medium-term basis is still under pressure, while the mildly bearish monthly MACD indicates a cautious longer-term outlook. This divergence between daily and higher timeframe MACD readings highlights the complexity of the current trend.

The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, providing no immediate impetus for a strong directional move based on momentum extremes.

Bollinger Bands on weekly and monthly charts remain sideways, indicating a consolidation phase without significant volatility expansion. This aligns with the recent sideways to mildly bullish trend shift, implying that the stock is in a phase of price discovery rather than trending decisively.

Additional Technical Measures: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator, which aggregates multiple rate-of-change measures, is mildly bearish on both weekly and monthly timeframes. This suggests that momentum is not yet robust enough to confirm a sustained uptrend, reinforcing the cautious tone set by the MACD.

Dow Theory analysis presents a mildly bullish weekly signal but no discernible trend on the monthly scale. This mixed reading indicates that while short-term price action may be improving, the broader market context remains uncertain.

On-Balance Volume (OBV), a volume-based indicator, shows a mildly bullish weekly trend but a mildly bearish monthly trend. The weekly OBV improvement suggests accumulation by traders in the short term, but the monthly decline points to longer-term distribution or lack of conviction among institutional investors.

Mojo Score and Grade Revision

MarketsMOJO assigns Sun Pharma a Mojo Score of 62.0, reflecting a moderate level of confidence in the stock’s fundamentals and technicals. The Mojo Grade was downgraded from Buy to Hold on 16 Feb 2026, signalling a more cautious stance amid the mixed technical signals and evolving price momentum. The Market Cap Grade remains at 1, indicating a large-cap status with stable market capitalisation.

This downgrade aligns with the technical indicators’ mixed messages and the stock’s recent sideways to mildly bullish trend shift. Investors should weigh these factors carefully, considering both the stock’s strong historical returns and the current technical uncertainty.

Sector and Industry Context

Sun Pharma operates within the Pharmaceuticals & Biotechnology sector, which has faced headwinds from regulatory scrutiny, pricing pressures, and evolving global healthcare dynamics. Despite these challenges, Sun Pharma’s long-term outperformance relative to the Sensex over three and five years underscores its resilience and growth potential.

However, the stock’s muted year-to-date and one-year returns relative to the broader market highlight the need for vigilance. Technical indicators suggest that while short-term momentum is improving, medium- and long-term trends remain fragile.

Investor Implications and Outlook

For investors, the current technical profile of Sun Pharma suggests a cautious approach. The bullish daily moving averages and mildly bullish weekly price trend indicate potential for near-term gains, but the bearish MACD and KST on higher timeframes counsel prudence. The neutral RSI and sideways Bollinger Bands further imply that the stock is in a consolidation phase, awaiting a catalyst for a decisive move.

Given the downgrade to a Hold rating and the Mojo Score of 62.0, investors may consider maintaining existing positions while monitoring for confirmation of a sustained uptrend. Those seeking entry points might wait for clearer bullish signals on weekly and monthly MACD or a breakout above recent resistance levels near ₹1,720 to ₹1,730.

Long-term investors should also factor in Sun Pharma’s strong multi-year returns and sector fundamentals, balancing technical caution with the company’s established market position and growth prospects.

Summary

Sun Pharmaceutical Industries Ltd’s technical momentum has shifted from sideways to mildly bullish, supported by daily moving averages and weekly price action. However, mixed signals from MACD, KST, and OBV across weekly and monthly timeframes temper enthusiasm. The downgrade from Buy to Hold by MarketsMOJO reflects this nuanced outlook. Investors should weigh the stock’s solid historical performance against current technical uncertainties, adopting a measured stance as the stock navigates consolidation and potential trend inflection points.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →